

## **Collaborative Working Executive Summary**

### **Project Name**

Bourne End and Wooburn Green Medical Centre (BEWGMC) Secondary Prevention Service

### **Between**

Bourne End and Wooburn Green Medical Centre And  
Recordati Pharmaceuticals Ltd

### **Project Start**

April 2025

### **Duration**

6 Months

### **Project Summary**

Bourne End and Wooburn Green Medical Centre (BEWGMC) have identified that a number of their patients, approximately 50, are not currently optimised for Cardiovascular Secondary Prevention in line with the current National and Buckinghamshire, Oxfordshire and Berkshire West Guidelines.

Recordati and the BEWGMC have agreed on this collaborative working project so that we can work together to implement a new service to optimise these patients.

The service will use an experienced GP with a Cardiovascular (CV) Disease specialism to review and optimise the patients across a range of CV risk factors, including blood pressure, LDL Cholesterol and residual CV risk indicated by elevated triglycerides, in with the aim of reducing the patient's risk of a future CV event.

### **Project Benefits**

#### **For Patients**

- Improved clinical care for patients, through identification of at-risk Patients and optimising secondary prevention therapies.
- Greater satisfaction of patients due to improved identification and proactive management of their cardiovascular risk through the additional capacity provided by the Secondary Prevention Service.

### **For BEWGMC**

- The Service may lead to reduction in recurrent cardiac events, with eventual medium and long-term saving for NHS and reduction in the downstream burden on the health system (e.g. hospitalisation) from recurrent cardiac events.
- The Service may lead to an increase in the number of patients achieving the Quality and Outcomes (QoF) framework targets for cardiovascular disease which may increase the QoF points achieved.

### **For Recordati**

- Increase in the appropriate use of medicines aligned with local and national guidance which includes Recordati's product.
- Increase in Patients identified and treated for secondary CVD risk factors, which may be relevant to the Recordati business.
- Increased knowledge about the identification and management of secondary prevention patients especially in relation to lipids.
- Increased knowledge about patient choices and reasons for declining evidence-based treatment options.
- Enhanced Recordati reputation and supporting the Recordati Mantra that "health, and the opportunity to live life to the fullest, is a right, not a privilege."

### **Financial Contribution**

The total cost of this project, including direct and indirect costs, is calculated at £8950.

Recordati's contribution to the project is £5337.50 (60% of total cost)

BEWGMC are covering the cost of premises, blood tests, IT, patient information systems, training and supervision of clinical staff.